NCT00211939 - CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients | Biotech Hunter

Enrollment

203

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

March 31, 2007

Conditions

CalcinosisArteriosclerosisHyperparathyroidism, Secondary

Interventions

DRUG

calcium acetate

667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level

DRUG

sevelamer

1-3 tablets t.i.d, titrated to serum phosphorus level

DRUG

atorvastatin

20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests

Trial Locations (1)

University of Texas Health Sciences Center, San Antonio